louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06104683: A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Official title: A Phase 2, Randomized Study of Pirtobrutinib Versus Placebo in Patients With Relapsing Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Relapsing Multiple Sclerosis
Multiple Sclerosis
Keywords: Relapsing Forms Multiple Sclerosis
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: Eli Lilly and Company
First posted: 2023-10-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.


Eligibility criteria: Inclusion Criteria:

* Participants must have been diagnosed with relapsing MS
* Participants must have one of the following

  1. at least 1 documented relapse within the previous year, or
  2. at least 2 documented relapse within the previous 2 years, or
  3. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

* Have had a diagnosis of primary progressive MS
* Have a history of another clinically significant neurological disease
* Had a relapse of MS within 30 days prior to randomization.

Primary outcomes:
measure: New T1 Gadolinium (Gd)-enhancing Lesions on Brain Magnetic Resonance Imaging (MRI) Per Scan
timeFrame: Week 8 and Week 12
measure: Number of New and/or Enlarging T2 Lesions
timeFrame: Week 12
Secondary outcomes:
measure: Total Number of T1 Gd-Enhancing Lesions Per Scan
timeFrame: Week 8 and Week 12
measure: Total Number of Gd-Enhancing Lesions Per Scan
timeFrame: Week 8 and Week 12
measure: Pharmacokinetics (PK): Plasma Concentration of Pirtobrutinib
timeFrame: Baseline to Week 12
Other outcomes:
Locations:
city: Tampa
country: United States
facility: University of South Florida
state: Florida
city: Houston
country: United States
facility: Clinical Trial Network
state: Texas
city: Seattle
country: United States
facility: Swedish Medical Center-501 E Hampden Ave
state: Washington
city: Guaynabo
country: Puerto Rico
facility: Caribbean Center For Clinical Research Inc
Study officials:
affiliation: Eli Lilly and Company
name: 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT03353883: Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?
Official title: Is Early Preparation With GnRh Agonists Injection on D-1 of Menses of Hormonal Replacement Cycle Improves Pregnancy Rate in Women With Impaired Ovulation and Undergoing Frozen-Thawed Embryo Transfer? A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Infertility, Female
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2017-11-27
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study intended to include \>200 infertile women with impaired ovulation who will be subjected to HRT at D-21 of previous menstrual cycle (Group A) or D-1 of menses of replacement cycle (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. Clinical pregnancy was diagnosed by measurement of β-human chorionic gonadotropin level and was confirmed 2-weeks later by TVU.

Detailed description: The study intended to include \>200 infertile women with impaired ovulation who will be subjected to HRT at D-21 of previous menstrual cycle (Group A) or D-1 of menses of replacement cycle (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 pronuclear embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-human chorionic gonadotropin level and was confirmed 2-weeks later by TVU.

Eligibility criteria: Inclusion Criteria:infertile women with impaired ovulation -

Exclusion Criteria:

-

Primary outcomes:
measure: pregnancy outcome
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Benha university hospital
state: Qaluibia
Study officials:
affiliation: Associate professor of obestetric and gynecology
name: Khalid M Salama, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Azimi Nekoo E, Chamani M, Shahrokh Tehrani E, Hossein Rashidi B, Davari Tanha F, Kalantari V. Artificial Endometrial Preparation for Frozen-Thawed Embryo Transfer with or without Pretreatment with Depot Gonadotropin Releasing Hormone Agonist in Women with Regular Menses. J Family Reprod Health. 2015 Mar;9(1):1-4.
Clinical trial NCT03212183: Evaluation of a Web-based Virtual Nursing Epilepsy Self-Management Intervention
Official title: Evaluation of a Web-based Virtual Nursing Intervention to Support Self-Management Among Adults With Epilepsy: A Preliminary Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Keywords: web-based intervention
self-management
nursing
epilepsy
seizures
Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Sponsor class: OTHER
Collaborators: name: Savoy Foundation
First posted: 2017-07-11
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this pilot randomized controlled trial is to evaluate a web-based virtual nursing intervention (ÉPI-TAVIE) in terms of 1) acceptability and feasibility, and; 2) preliminary efficacy.


Eligibility criteria: Inclusion Criteria:

* to be a patient of the Clinique d'épilepsie du Centre Hospitalier de l'Université de Montréal
* to be able to read and understand French
* to have access to the Internet

Exclusion Criteria:

* having an uncontrolled psychiatric or cognitive condition

Primary outcomes:
measure: Self-management
timeFrame: 3 months
Secondary outcomes:
measure: Acceptability of the intervention
timeFrame: 1 month
measure: Feasibility of the intervention
timeFrame: 1 month
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal
state: Quebec
Study officials:
affiliation: CRCHUM, Université de Montréal
name: José Côté, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: CHUM, Université de Montréal, CRCHUM
name: Dang Khoa Nguyen, PhD
role: STUDY_CHAIR
affiliation: CHUM, Université de Montréal, CRCHUM
name: Line Beaudet, PhD
role: STUDY_CHAIR
affiliation: Polytechnique Montréal
name: Yann-Gaël Guéhéneuc, PhD
role: STUDY_CHAIR
affiliation: CHUM
name: Vanessa Léger, BScN
role: STUDY_CHAIR
References:
citation: Cote J, Beaudet L, Auger P, Rouleau G, Chicoine G, Leger V, Keezer M, Reid MA, Nguyen DK. Evaluation of a web-based virtual nursing intervention to support self-management among adults with epilepsy: A mixed-methods study. Epilepsy Behav. 2021 Jan;114(Pt A):107581. doi: 10.1016/j.yebeh.2020.107581. Epub 2020 Nov 25.
Clinical trial NCT01137383: Pegaferon and Ribavirin for Hepatitis C
Official title: Safety and Efficacy of Locally Manufactured Pegylated Interferon in Hepatitis C Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatitis C
Keywords: Hepatitis C
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
Collaborators: name: Pars No Tarkib Co
First posted: 2010-06-04
Enrollment: 108
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of a locally produced 40KD pegylated interferon alpha-2a (Pegaferon) in patients with hepatitis C. 100 patients will be treated using standard guidelines for hepatitis C. Response to treatment and side effects will be recorded.

Detailed description: The product is locally produced and needs to be evaluated in terms of efficacy and safety.

Eligibility criteria: Inclusion Criteria:

* Chronic hepatitis C
* Age between 15 and 65

Exclusion Criteria:

* previous treatment for chronic hepatitis C
* co-infection with human immunodeficiency virus or hepatitis B virus
* major thalassemia or hemophilia
* active drug user
* being treated for major depression or psychosis
* decompensated cirrhosis
* serum creatinine \> 1.5 mg/dL
* solid organ transplant
* untreated thyroid disease
* uncontrolled diabetes mellitus
* uncontrolled autoimmune disease
* advanced cardiac or pulmonary disease.
* planning to become pregnant in the next 1.5 years
* patients with inadequate contraception
* not consenting to the study

Primary outcomes:
measure: Sustained viral response
timeFrame: 6 months after end of treatment
Secondary outcomes:
measure: Adverse drug events
timeFrame: 18 months from start of treatment
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Emam Hospital
city: Tehran
country: Iran, Islamic Republic of
facility: Shariati Hospital
Study officials:
affiliation: Tehran University of Medical Sciences
name: Reza Malekzadeh, MD
role: STUDY_CHAIR
References:
citation: Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, Zamini H, Shahzamani K, Merat S, Nassiri-Toosi M. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010 Jul;13(4):306-12.
Clinical trial NCT00837083: Evaluation of Crestor® (Rosuvastatin) in Daily Practice
Official title: Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: hypercholesterolemia
cholesterol
LDL-cholesterol
rosuvastatin
Crestor
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-02-05
Enrollment: 602
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients (outpatient or hospitalised) in whom Crestor is indicated according to the current Summary of product characteristics (SPC)

Brief summary: This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL cholesterol level between the first and the second visit after 12 weeks.


Eligibility criteria: Inclusion Criteria:

* a patient with hypercholesterolemia who has been prescribed Crestoraccording to physician's judgement, irrespective of the inclusion in the study.
* no treatment with any statin in the last 3 months

Exclusion Criteria:

* hypersensitivity to rosuvastatin or any other ingredient of Crestor
* active liver disease, severe renal insufficiency
* myopathy or predisposing risk factors for myopathy/ rhabdomyolysis
* woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Primary outcomes:
measure: LDL-cholesterol reduction
timeFrame: 12 weeks
Secondary outcomes:
measure: achievement of target levels of total cholesterol and LDL-cholesterol
timeFrame: 12 weeks
measure: patient compliance
timeFrame: 12 weeks
measure: change in coronary risk
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: University Medical Centre Ljubljana
name: Matija Cevc, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00969683: Double-Lumen Tube With or Without a Carinal Hook
Official title: Comparison Between Left Double-lumen Tube With or Without a Carinal Hook During Lung Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anesthesia
Lead sponsor: Hopital Foch
Sponsor class: OTHER
First posted: 2009-09-01
Enrollment: 184
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Most teams use a left double-lumen tube. The double-lumen tube is available with or without a carinal hook. The hook is supposed to facilitate the positioning of the tube and avoid the mobilization of the tube during surgery. The use of double-lumen tubes with a hook is large in Europe and quite unknown in US. The literature is poor, containing only few case reports.

The purpose of this research is to compare the two types of left double-lumen tube.


Eligibility criteria: Inclusion Criteria:

* patients scheduled for lung surgery requiring one-lung ventilation

Exclusion Criteria:

* pregnancy
* ASA class 4
* prevision of difficult intubation or of pulmonary aspiration

Primary outcomes:
measure: time required to initially position the assigned tube
timeFrame: end of anesthesia
Secondary outcomes:
measure: degree of lung collapse
timeFrame: end of anesthesia
measure: number of intraoperatively FOB examinations
timeFrame: end of anesthesia
measure: Glottic or tracheo-bronchial lesion
timeFrame: end of hospitalisation
measure: Sore throat or hoarse voice
timeFrame: end of hospitalisation
Other outcomes:
Locations:
city: Suresnes
country: France
facility: Service d'Anesthésie, Hôpital Foch
Study officials:
affiliation: Hôpital Foch
name: Marc Fischler, MD
role: STUDY_CHAIR
References:
citation: Dumans-Nizard V, Parquin JF, Moyer JD, Dreyfus JF, Fischler M, Le Guen M. Left double-lumen tube with or without a carinal hook: A randomised controlled trial. Eur J Anaesthesiol. 2015 Jun;32(6):418-24. doi: 10.1097/EJA.0000000000000201.
Clinical trial NCT05224583: Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
Official title: Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant Recipients: A Retrospective Single-Center Review
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Polyomavirus Infections
BK Viremia
Liver Transplant Infection
Kidney Transplant Infection
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2022-02-04
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).

Brief summary: The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.

Detailed description: The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%. Immunosuppression reduction is the management cornerstone for BKV and has been shown to be effective at clearing the virus while maintaining graft function in both kidney alone and simultaneous kidney-pancreas transplant recipients. However, there is a lack of published data on the prevalence and outcomes in simultaneous liver-kidney (SLK) transplant recipients.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* SLK recipients transplanted at MDMC between 2015-2020

Exclusion Criteria:

* Below 18 years of age
* Patients who did not undergo SLK transplant at MDMC

Primary outcomes:
measure: To characterize the prevalence of BKV in the SLK patient population at MDMC.
timeFrame: over a 6-year period (2015 to 2020).
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
affiliation: Methodist Health System
name: Lori Kautzman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06394583: LUS AT BIRTH IN INFANTS BORN BEFORE 26 WEEKS
Official title: DESCRIPTION OF THE LUNG ULTRASOUND PATTERN IN INFANTS UNDER 26 WEEKS OF GESTATION: A NATIONAL MULTICENTER STUDY
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Extremely Low Birth Weight Infants
Respiratory Distress Syndrome, Newborn
Keywords: lung ultrasound
premature infant
extremely low birth weight infants
Lead sponsor: Andaluz Health Service
Sponsor class: OTHER_GOV
First posted: 2024-05-01
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants born before 26 weeks in any of the centers included in the registry.

Brief summary: All infants born before 26 weeks born in a hospital included in the registry will receive a LU at birth, before the first dose of surfactant. We will register as well the length of IMV, NIV or the need of IMV in the whole sample.


Eligibility criteria: Inclusion Criteria:

* Infants born before 26 weeks at any of the participant hospitals.

Exclusion Criteria:

* received surfactant before LU
* redirection of care
* severe malformations of cromosomopathies
* unable to perform LU

Primary outcomes:
measure: Description of LU patterns
timeFrame: at birth
Secondary outcomes:
measure: need of IMV
timeFrame: during NICU admission
measure: length of IMV
timeFrame: during NICU admission
measure: length of NIV
timeFrame: during NICU admission
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01323283: Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children
Official title: Intervention Study of the Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects of Omega-3 Fatty Acids in 8 Year Old Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lifestyle-related Condition
Overweight and Obesity
Essential Fatty Acid Deficiency
Keywords: Omega-3
physical activity
children
obesity
sedentary
accelerometry
BMI
fatty acids
inflammatory markers
intervention
randomized
double blind
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
Collaborators: name: Midsona AB
name: Forskningsrådet för arbetsliv och socialvetenskap, FAS
First posted: 2011-03-25
Enrollment: 423
Sex: ALL
Minimum age (years): 7
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study hypothesizes that supplementation of omega-3 fatty acids (OM3) can increase physical activity, inhibit rapid gain in body weight and BMI in both sedentary and normally active 8 year old children. The purpose is secondarily to explore patterns of associations between OM3 supplementation, baseline and follow-up levels in all studied parameters. The study also aims to study if basal levels of OM3 are correlated with physical activity and to study if there is an association between basal levels of OM3 and the effect of OM3 supplementation on physical activity. To study if there is an effect of OM3 supplementation on triglyceride and LDL cholesterol levels and to study if there are more pronounced effects on children with higher levels. To study if OM3 supplementation, compared with placebo reduce weight increase among children at risk to become overweight. To study if there is an association between effects of OM3 on physical activity, weight and risk markers in blood. To study if there are any gender differences.


Eligibility criteria: Inclusion Criteria:

* Children in second grade of Swedish primary school willing to participate

Primary outcomes:
measure: Total physical activity
timeFrame: 15 weeks
measure: Body mass
timeFrame: 15 weeks
Secondary outcomes:
measure: BMI
timeFrame: 15 weeks
measure: Cardiovascular risk markers
timeFrame: 15 weeks
measure: Childrens reported quality of life
timeFrame: 15 weeks
measure: Perceived motor skill
timeFrame: 15 weeks
measure: Self reported physical activity
timeFrame: 15 weeks
Other outcomes:
Locations:
city: Huddinge
country: Sweden
facility: Karolinska Universitetssjukhuset
state: Södermanland
Study officials:
affiliation: Karolinska Institutet
name: Claude Marcus, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03140683: Predictors of Scar Dehiscence in Patients With Previous Caesarean Section
Official title: Predictors of Scar Dehiscence in Patients With Previous Caesarean Section; a Study of Different Variables Tenderness Versus Non-stress Test
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cesarean Section; Dehiscence
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-05-04
Enrollment: 180
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study sample will be collected from Women's Health Hospital of Assiut University and Assuit Health Insurance Hospital

Brief summary: In recent decades, the percentage of Cesarean section deliveries has dramatically increased in most countries. Concomitantly, the rates of vaginal birth after Cesarean have decreased steadily.

The pregnant women with previous Cesarean section face a difficult choice for their next delivery between a trial of labor after Cesarean or repeat caesarean section delivery.

The performance of multiple Cesarean section exposes women to greater risks of complications; furthermore, the risk of complications increases with each subsequent Cesarean section.

In fact, women with previous Cesarean section are more likely to experience short and long-term maternal complications in future pregnancies, or a trial of labor after Cesarean, with the risk of \[uterine dehiscence, uterine rupture, genitourinary tract damage, hemorrhage and hysterectomy, abnormal placentation (placenta previa and placenta accreta) and difficulties during surgery


Eligibility criteria: Inclusion Criteria:

1. Pregnant full-term 37-42 weeks.
2. Previous one caesarean section

Exclusion Criteria:

1. Absolute indication of cesarean section in previous and in current pregnancy
2. Pregnant women with Hemoglobin \<9
3. Pregnant women with bleeding tendency
4. Pregnant women with collagen disease
5. Pregnant women with pre-eclampsia and eclampsia
6. Pregnant women with gestational diabetes
7. Multiple pregnancy

Primary outcomes:
measure: number of women with dehisensce scar and Non-stress test abnormalities
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut Faculty of Medicine
Study officials:
References: